Drugs / Recombinant human eythropoietin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05691257 Background | Feb → Aug 2023 | anemia, chronic kidney disease, heart failure | China-Japan Friendship Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant human eythropoietin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05691257 ↗ |
| Known as | RH-EPO | “Other drugs to treat anemia include: Recombinant human eythropoietin (RH-EPO), iron agents (ferrous succinate, polysaccharide iron complex, iron sucrose, etc.)” NCT05691257 ↗ |